专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009039127A1 URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C 审中-公开
标题翻译：尿嘧啶或用于治疗乙型肝炎的衍生物C
公开(公告)号：WO2009039127A1
公开(公告)日：2009-03-26
申请号：PCT/US2008/076576
申请日：2008-09-17
申请人： ABBOTT LABORATORIES , WAGNER, Rolf , TUFANO, Michael D. , STEWART, Kent D. , ROCKWAY, Todd W. , RANDOLPH, John T. , PRATT, John K. , MOTTER, Christopher E. , MARING, Clarence J. , LONGENECKER, Kenton L. , LIU, Yaya , LIU, Dachun , KRUEGER, Allan C. , KATI, Warren M. , HUTCHINSON, Douglas K. , HUANG, Peggy P. , FLENTGE, Charles A. , DONNER, Pamela L. , DEGOEY, David A. , BETEBENNER, David A. , BARNES, David M. , CHEN, Shuang , FRANCZYK II, Thaddeus S. , GAO, Yi , HAIGHT, Anthony R. , HENGEVELD, John E. , HENRY, Rodger F. , KOTECKI, Brian J. , LOU, Xiaochun , SARRIS, Kathy , ZHANG, Geoff G. Z.
发明人： WAGNER, Rolf , TUFANO, Michael D. , STEWART, Kent D. , ROCKWAY, Todd W. , RANDOLPH, John T. , PRATT, John K. , MOTTER, Christopher E. , MARING, Clarence J. , LONGENECKER, Kenton L. , LIU, Yaya , LIU, Dachun , KRUEGER, Allan C. , KATI, Warren M. , HUTCHINSON, Douglas K. , HUANG, Peggy P. , FLENTGE, Charles A. , DONNER, Pamela L. , DEGOEY, David A. , BETEBENNER, David A. , BARNES, David M. , CHEN, Shuang , FRANCZYK II, Thaddeus S. , GAO, Yi , HAIGHT, Anthony R. , HENGEVELD, John E. , HENRY, Rodger F. , KOTECKI, Brian J. , LOU, Xiaochun , SARRIS, Kathy , ZHANG, Geoff G. Z.
IPC分类号： C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61P31/12 , A61K31/513
CPC分类号： A61K31/513 , A61K31/5377 , C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , C07D417/14
摘要： Present application relates to the compounds of formula I useful to treat hepatitis C (HCV) infections. In the structure of the disclosed compounds is the uracil or thymine derivative linked via a phenylene into either fused 2-ring cyclic system (R6) or alternatively via additional two-atom linker (L) to a 5-6 membered monocycle (R6). Application further discloses polymorphs and pseudopolymorphs of two specific compounds: N-(6(3-t-butyl-5-(2>4-dioxo-3,4-dihydropyrimidin-1 (2H)- y!)2-methoxy-phenyl)naphthalen-2-yl)methanesulfonamide and (E)-N-(4(3-t- butyl-5-(2,4-dioxo-3)4-dihydropyrimidin-1 (2H)-yl)2-methoxy-styryl- phenyl)methanesulfonamide.
摘要翻译：本申请涉及可用于治疗丙型肝炎（HCV）感染的式I化合物。所公开的化合物的结构是通过亚苯基连接成稠合的2-环环系（R6）或者另外通过另外的两个原子连接基（L）与5-6元单环（R6）连接的尿嘧啶或胸腺嘧啶衍生物。应用进一步公开了两种特定化合物的多晶型物和假多晶型物：N-（6（3-叔丁基-5-（2,4-二氧代-3,4-二氢嘧啶-1（2H） - 基）-2-甲氧基 - 苯基）萘-2-基）甲磺酰胺和（E）-N-（4（3-叔丁基-5-（2,4-二氧代-3）4-二氢嘧啶-1（2H） - 基）2-甲氧基 - 苯乙烯基 - 苯基）甲磺酰胺。

2. 发明申请

WO2009039135A1 N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS 审中-公开
标题翻译：用作丙型肝炎病毒（HCV）抑制剂的N-苯基二氧化二氢亚胺嘧啶
公开(公告)号：WO2009039135A1
公开(公告)日：2009-03-26
申请号：PCT/US2008/076594
申请日：2008-09-17
申请人： ABBOTT LABORATORIES , DONNER, Pamela L. , RANDOLPH, John T. , KRUEGER, Allan C. , BETEBENNER, David A. , HUTCHINSON, Douglas K. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton L. , MARING, Clarence J. , PRATT, John K. , ROCKWAY, Todd W. , STEWART, Kent D. , WAGNER, Rolf , BARNES, David M. , CHEN, Shuang , FRANCZYK II, Thaddeus S. , GAO, Yi , HAIGHT, Anthony R. , HENGEVELD, John E. , HENRY, Rodger F. , KOTECKI, Brian J. , LOU, Xiaochun , ZHANG, Geoff G. Z.
发明人： DONNER, Pamela L. , RANDOLPH, John T. , KRUEGER, Allan C. , BETEBENNER, David A. , HUTCHINSON, Douglas K. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton L. , MARING, Clarence J. , PRATT, John K. , ROCKWAY, Todd W. , STEWART, Kent D. , WAGNER, Rolf , BARNES, David M. , CHEN, Shuang , FRANCZYK II, Thaddeus S. , GAO, Yi , HAIGHT, Anthony R. , HENGEVELD, John E. , HENRY, Rodger F. , KOTECKI, Brian J. , LOU, Xiaochun , ZHANG, Geoff G. Z.
IPC分类号： C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D239/553 , A61K31/513 , A61K31/506 , A61P31/14
CPC分类号： C07D239/22 , A61K31/513 , C07D239/54 , C07D239/553 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. The compounds are usefull in the treatment of hepatitis C and are of the following general structure: Formula (I)
摘要翻译：本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。该化合物在丙型肝炎的治疗中是有用的，具有以下通用结构：式（I）

3. 发明申请

WO2009039134A1 ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF 审中-公开
标题翻译：抗感染性吡啶类及其用途
公开(公告)号：WO2009039134A1
公开(公告)日：2009-03-26
申请号：PCT/US2008/076592
申请日：2008-09-17
申请人： ABBOTT LABORATORIES , FLENTGE, Charles, A. , HUTCHINSON, Douglas, K. , BETEBENNER, David, A. , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , KRUEGER, Allan, C. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton, L. , MARING, Clarence, J. , MOTTER, Christopher, E. , PRATT, John, K. , RANDOLPH, John, T. , ROCKWAY, Todd, W. , STEWART, Kent, D. , WAGNER, Rolf , BARNES, David, M. , CHEN, Shuang , FRANCZYK, Thaddeus, S., II , GAO, Yi , HAIGHT, Anthony, R. , HENGEVELD, John, E. , KOTECKI, Brian, J. , LOU, Xiaochun , ZHANG, Geoff, G., Z.
发明人： FLENTGE, Charles, A. , HUTCHINSON, Douglas, K. , BETEBENNER, David, A. , DEGOEY, David, A. , DONNER, Pamela, L. , KATI, Warren, M. , KRUEGER, Allan, C. , LIU, Dachun , LIU, Yaya , LONGENECKER, Kenton, L. , MARING, Clarence, J. , MOTTER, Christopher, E. , PRATT, John, K. , RANDOLPH, John, T. , ROCKWAY, Todd, W. , STEWART, Kent, D. , WAGNER, Rolf , BARNES, David, M. , CHEN, Shuang , FRANCZYK, Thaddeus, S., II , GAO, Yi , HAIGHT, Anthony, R. , HENGEVELD, John, E. , KOTECKI, Brian, J. , LOU, Xiaochun , ZHANG, Geoff, G., Z.
IPC分类号： C07D239/22 , C07D239/54 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K31/513 , A61P31/12
CPC分类号： C07D239/54 , A61K31/513 , A61K45/06 , C07D239/22 , C07D401/10 , C07D403/10 , C07D405/10 , C07D409/10 , C07D413/10 , C07D417/10 , A61K2300/00
摘要： This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
摘要翻译：本发明涉及：（a）特别是抑制HCV的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

4. 发明申请

WO2012051361A1 ANTI-VIRAL COMPOUNDS 审中-公开
标题翻译：反虚构化合物
公开(公告)号：WO2012051361A1
公开(公告)日：2012-04-19
申请号：PCT/US2011/056045
申请日：2011-10-12
申请人： ABBOTT LABORATORIES , DEGOEY, David A. , KATI, Warren M. , HUTCHINS, Charles W. , DONNER, Pamela L. , KRUEGER, Allan C. , RANDOLPH, John T. , MOTTER, Christopher E. , NELSON, Lissa T. , PATEL, Sachel V. , MATULENKO, Mark A. , KEDDY, Ryan G. , JINKERSON, Tammie K. , GAO, Yi , LIU, Dachun , PRATT, John K. , ROCKWAY, Todd W. , MARING, Clarence J. , HUTCHINSON, Douglas K. , FLENTGE, Charles A. , WAGNER, Rolf , TUFANO, Michael D. , BETEBENNER, David A. , SARRIS, Kathy , WOLLER, Kevin R. , WAGAW, Sebel H. , CALIFANO, Jean C. , LI, Wenke , CASPI, Daniel D. , BELLIZZI, Mary E. , CARROLL, William A.
发明人： DEGOEY, David A. , KATI, Warren M. , HUTCHINS, Charles W. , DONNER, Pamela L. , KRUEGER, Allan C. , RANDOLPH, John T. , MOTTER, Christopher E. , NELSON, Lissa T. , PATEL, Sachel V. , MATULENKO, Mark A. , KEDDY, Ryan G. , JINKERSON, Tammie K. , GAO, Yi , LIU, Dachun , PRATT, John K. , ROCKWAY, Todd W. , MARING, Clarence J. , HUTCHINSON, Douglas K. , FLENTGE, Charles A. , WAGNER, Rolf , TUFANO, Michael D. , BETEBENNER, David A. , SARRIS, Kathy , WOLLER, Kevin R. , WAGAW, Sebel H. , CALIFANO, Jean C. , LI, Wenke , CASPI, Daniel D. , BELLIZZI, Mary E. , CARROLL, William A.
IPC分类号： C07D403/14
CPC分类号： A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
摘要： Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
摘要翻译：描述了有效抑制丙型肝炎病毒（HCV）复制的化合物。本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

5. 发明申请

WO2012116257A1 ANTI-VIRAL COMPOUNDS 审中-公开
标题翻译：抗病毒化合物
公开(公告)号：WO2012116257A1
公开(公告)日：2012-08-30
申请号：PCT/US2012/026456
申请日：2012-02-24
申请人： ABBVIE INC. , DEGOEY, David A. , KATI, Warren M. , HUTCHINS, Charles W. , DONNER, Pamela L. , KRUEGER, Allan C. , RANDOLPH, John T. , PATEL, Sachin V. , MATULENKO, Mark A. , KEDDY, Ryan G. , JINKERSON, Tammie K. , LIU, Danchun , PRATT, John K. , ROCKWAY, Todd W. , MARING, Clarence J. , HUTCHINSON, Douglas H. , FLENTGE, Charles A. , WAGNER, Rolf , BETEBENNER, David A. , SARRIS, Kathy , WOLLER, Kevin R. , CARROLL, William A. , GAO, Yi
发明人： DEGOEY, David A. , KATI, Warren M. , HUTCHINS, Charles W. , DONNER, Pamela L. , KRUEGER, Allan C. , RANDOLPH, John T. , PATEL, Sachin V. , MATULENKO, Mark A. , KEDDY, Ryan G. , JINKERSON, Tammie K. , LIU, Danchun , PRATT, John K. , ROCKWAY, Todd W. , MARING, Clarence J. , HUTCHINSON, Douglas H. , FLENTGE, Charles A. , WAGNER, Rolf , BETEBENNER, David A. , SARRIS, Kathy , WOLLER, Kevin R. , CARROLL, William A. , GAO, Yi
IPC分类号： C07D403/14 , A61K31/4184 , A61K31/4164 , A61P31/14
CPC分类号： C07D403/14 , C07D207/16
摘要： Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
摘要翻译：描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。

6. 发明申请

WO2011156578A1 SOLID COMPOSITIONS 审中-公开
标题翻译：固体组合物
公开(公告)号：WO2011156578A1
公开(公告)日：2011-12-15
申请号：PCT/US2011/039769
申请日：2011-06-09
申请人： ABBOTT LABORATORIES , LIEPOLD, Bernd , JUNG, Tina , HOLIG, Peter , SCHROEDER, Rudolf , SEVER, Nancy E. , LAFOUNTAINE, Justin , SINCLAIR, Brent D. , GAO, Yi , WU, Jianwei , ERICKSON, Bryan K. , KULLMANN, Simon , WESTEDT, Ulrich , PAULI, Mirko , HEITERMANN, Tanja , KOENIG, Renato , THIEL, Madlen
发明人： LIEPOLD, Bernd , JUNG, Tina , HOLIG, Peter , SCHROEDER, Rudolf , SEVER, Nancy E. , LAFOUNTAINE, Justin , SINCLAIR, Brent D. , GAO, Yi , WU, Jianwei , ERICKSON, Bryan K. , KULLMANN, Simon , WESTEDT, Ulrich , PAULI, Mirko , HEITERMANN, Tanja , KOENIG, Renato , THIEL, Madlen
IPC分类号： A61K9/14 , A61K9/16 , A61K9/20 , A61K31/00
CPC分类号： A61K31/4025 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1694 , A61K9/2027 , A61K9/2054 , A61K31/00
摘要： The present invention features solid compositions comprising Compound I A , I B , I C or I D , or a pharmaceutically acceptable salt thereof, in an amorphous form. In one embodiment, Compound I A , I B , I C or I D , or a pharmaceutically acceptable salt thereof, is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.
摘要翻译：本发明的特征在于包含无定形形式的包含化合物1A，IB，IC或ID的固体组合物或其药学上可接受的盐。在一个实施方案中，将化合物1A，IB，IC或ID或其药学上可接受的盐配制在包含药学上可接受的亲水性聚合物，优选药学上可接受的表面活性剂的无定形固体分散体中。

7. 发明申请

WO2006135480A2 PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2006135480A2
公开(公告)日：2006-12-21
申请号：PCT/US2006/013121
申请日：2006-04-07
申请人： ABBOTT LABORATORIES , ZHU, Tong , JU, Tzuchi, R. , DAVILA, Claudia, M. , ENGH, Kevin, R. , GAO, Yi , GUSTAVSON, Linda, E. , JAYARAMAN, Shyamala, C. , LEBLOND, David , LEE, Dennis, Y.
发明人： ZHU, Tong , JU, Tzuchi, R. , DAVILA, Claudia, M. , ENGH, Kevin, R. , GAO, Yi , GUSTAVSON, Linda, E. , JAYARAMAN, Shyamala, C. , LEBLOND, David , LEE, Dennis, Y.
IPC分类号： A61K9/48 , A61K9/20 , A61K9/00 , A61K31/192 , A61K9/28 , A61K9/50
CPC分类号： A61K9/5026 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K9/2846 , A61K9/2866 , A61K9/4808 , A61K31/192
摘要： The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid.
摘要翻译：本发明涉及包含2- [4-（4-氯苯甲酰基）苯氧基] -2-甲基 - 丙酸中的至少一种的活性剂，2- [4-（4-氯苯甲酰基）苯氧基] -2-甲基 - 丙酸或缓冲的2- [4-（4-氯苯甲酰基）苯氧基] -2-甲基 - 丙酸。

8. 发明申请

WO2008046052A1 PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2008046052A1
公开(公告)日：2008-04-17
申请号：PCT/US2007/081267
申请日：2007-10-12
申请人： ABBOTT LABORATORIES , GAO, Yi , TZUCHI, R. Ju , LEE, Dennis Y. , NGUYEN, Nicole , WU, Hauiliang
发明人： GAO, Yi , TZUCHI, R. Ju , LEE, Dennis Y. , NGUYEN, Nicole , WU, Hauiliang
IPC分类号： A61K31/192 , A61K9/20 , A61K9/28 , A61K9/16
CPC分类号： A61K9/1623 , A61K9/1652 , A61K9/2018 , A61K9/2054 , A61K9/2846 , A61K31/192
摘要： The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media.
摘要翻译：本发明提供一种在亲水性聚合物基质中包含活性剂的改性释放制剂，其中活性剂是非诺贝酸盐，其中制剂在体外溶出中的释放速率基本上与溶出介质的离子强度无关。

9. 发明申请

WO2011156361A2 SOLID DISPERSIONS CONTAINING KINASE INHIBITORS 审中-公开
标题翻译：含有激酶抑制剂的固体分散体
公开(公告)号：WO2011156361A2
公开(公告)日：2011-12-15
申请号：PCT/US2011/039430
申请日：2011-06-07
申请人： ABBOTT LABORATORIES , MILLER, Jonathan , GOKHALE, Rajeev , SCHMITT, Eric, A. , GAO, Yi , LAFOUNTAINE, Justin , DIAS, Lloyd
发明人： MILLER, Jonathan , GOKHALE, Rajeev , SCHMITT, Eric, A. , GAO, Yi , LAFOUNTAINE, Justin , DIAS, Lloyd
IPC分类号： A61K9/14 , A61K9/16 , A61K31/4743
CPC分类号： A61K9/145 , A61K9/146 , A61K9/1617 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2077 , A61K31/4743
摘要： A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N'-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer.
摘要翻译：固体分散体以基本上非结晶的形式包含激酶抑制化合物，例如N-（4- {4-氨基-7- [1-（2-羟乙基）-1H-吡唑-4-基]噻吩并[ 3,2-c]吡啶-3-基}苯基）-N' - （3-氟苯基）脲，分散在固体基质中，其包含（a）药学上可接受的水溶性聚合物载体和（b）药学上可接受的表面活性剂。制备这种固体分散体的方法包括将化合物，聚合物载体和表面活性剂溶解在合适的溶剂中，并除去溶剂以提供包含聚合物载体和表面活性剂的固体基质，并使化合物分散在基本上不结晶形成。固体分散体适合于有需要的受试者口服给药以治疗癌症。

10. 发明申请

WO2013134929A1 METHOD AND APPARATUS FOR MULTI-STAGE ADAPTIVE VOLUME CONTROL 审中-公开
标题翻译：用于多级自适应体积控制的方法和装置
公开(公告)号：WO2013134929A1
公开(公告)日：2013-09-19
申请号：PCT/CN2012/072278
申请日：2012-03-13
申请人： MOTOROLA SOLUTIONS, INC. , GAO, Yi , BARRUS, James D. , KUSHNER, William M. , LIU, Yu , XIAO, Li
发明人： GAO, Yi , BARRUS, James D. , KUSHNER, William M. , LIU, Yu , XIAO, Li
IPC分类号： H04M1/60
CPC分类号： H03G3/20 , H04M1/6041
摘要： A method and apparatus for adaptively controlling the audio output (122) of a communication device (114) according to the noise characteristics of the receiver listening environment (119). An output volume for the communication device (114) is set by a user (e.g., listener 118). The communication device (114) can intermittently sample ambient noise (116) of its environment (119). A minimum signal to noise threshold can be established for audio output (122). A total adjustment for the audio output (122) is established based on the ambient noise (116), the user set output volume, and the minimum signal to noise threshold. The total adjustment is a product of a software volume adjustment (230) and a hardware gain adjustment (240). The software volume adjustment (230) and the hardware gain adjustment (240) is adaptively applied when the communication device (114) outputs audio (122).
摘要翻译：一种用于根据接收机收听环境（119）的噪声特性自适应地控制通信设备（114）的音频输出（122）的方法和装置。通信设备（114）的输出音量由用户（例如，听众118）设置。通信设备（114）可以间歇地对其环境（119）的环境噪声（116）进行采样。可以为音频输出（122）建立最小信号噪声阈值。基于环境噪声（116），用户设定输出音量和最小信号噪声阈值来建立音频输出（122）的总体调整。总体调整是软件音量调整（230）和硬件增益调整（240）的产物。当通信设备（114）输出音频（122）时，自适应地应用软件音量调节（230）和硬件增益调整（240）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式